The Role of NAD+, SIRTs Interactions in Stimulating and Counteracting Carcinogenesis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 May 13

PMID 37175631

Authors

Ekaterina Podyacheva

Yana Toropova

Affiliations

Soon will be listed here.

Abstract

The World Health Organization has identified oncological diseases as one of the most serious health concerns of the current century. Current research on oncogenesis is focused on the molecular mechanisms of energy-biochemical reprogramming in cancer cell metabolism, including processes contributing to the Warburg effect and the pro-oncogenic and anti-oncogenic roles of sirtuins (SIRTs) and poly-(ADP-ribose) polymerases (PARPs). However, a clear understanding of the interaction between NAD, SIRTs in cancer development, as well as their effects on carcinogenesis, has not been established, and literature data vary greatly. This work aims to provide a summary and structure of the available information on NAD, SIRTs interactions in both stimulating and countering carcinogenesis, and to discuss potential approaches for pharmacological modulation of these interactions to achieve an anticancer effect.

Citing Articles

Structure-Function Insights into the Dual Role in Nucleobase and Nicotinamide Metabolism and a Possible Use in Cancer Gene Therapy of the URH1p Riboside Hydrolase.

Carriles A, Muzzolini L, Minici C, Tornaghi P, Patrone M, Degano M Int J Mol Sci. 2024; 25(13).

PMID: 39000137 PMC: 11241417. DOI: 10.3390/ijms25137032.

Mitochondrial SIRT3 as a protective factor against cyclosporine A-induced nephrotoxicity.

Kim J, Jo M, Bae S, Ahn S, Ko G, Kwon Y Sci Rep. 2024; 14(1):10143.

PMID: 38698042 PMC: 11065982. DOI: 10.1038/s41598-024-60453-4.

References

Saunders L, Verdin E . Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007; 26(37):5489-504. DOI: 10.1038/sj.onc.1210616. View

Alhazzazi T, Kamarajan P, Joo N, Huang J, Verdin E, DSilva N . Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 2011; 117(8):1670-8. PMC: 3117020. DOI: 10.1002/cncr.25676. View

Wang H, Li J, Huang R, Fang L, Yu S . SIRT4 and SIRT6 Serve as Novel Prognostic Biomarkers With Competitive Functions in Serous Ovarian Cancer. Front Genet. 2021; 12:666630. PMC: 8320514. DOI: 10.3389/fgene.2021.666630. View

Keshari K, Wilson D, van Criekinge M, Sriram R, Koelsch B, Wang Z . Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor. Prostate. 2015; 75(14):1601-9. PMC: 4537380. DOI: 10.1002/pros.23036. View

DAmours D, Desnoyers S, DSilva I, Poirier G . Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999; 342 ( Pt 2):249-68. PMC: 1220459. View

Carbone F, Liberale L, Bonaventura A, Vecchie A, Casula M, Cea M . Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. Compr Physiol. 2017; 7(2):603-621. DOI: 10.1002/cphy.c160029. View

Fan J, Shan C, Kang H, Elf S, Xie J, Tucker M . Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell. 2014; 53(4):534-48. PMC: 3943932. DOI: 10.1016/j.molcel.2013.12.026. View

Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q . USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep. 2013; 5(6):1639-49. PMC: 4007576. DOI: 10.1016/j.celrep.2013.11.029. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

10.

Singh N, Pay S, Bhandare S, Arimpur U, Motea E . Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel). 2020; 12(4). PMC: 7226473. DOI: 10.3390/cancers12040972. View

11.

Von Heideman A, Berglund A, Larsson R, Nygren P . Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol. 2009; 65(6):1165-72. DOI: 10.1007/s00280-009-1125-3. View

12.

Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S . Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem. 2010; 285(11):8375-82. PMC: 2832987. DOI: 10.1074/jbc.M109.090266. View

13.

Nogueiras R, Habegger K, Chaudhary N, Finan B, Banks A, Dietrich M . Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012; 92(3):1479-514. PMC: 3746174. DOI: 10.1152/physrev.00022.2011. View

14.

Yaku K, Okabe K, Hikosaka K, Nakagawa T . NAD Metabolism in Cancer Therapeutics. Front Oncol. 2019; 8:622. PMC: 6315198. DOI: 10.3389/fonc.2018.00622. View

15.

Kumar S, Lombard D . Functions of the sirtuin deacylase SIRT5 in normal physiology and pathobiology. Crit Rev Biochem Mol Biol. 2018; 53(3):311-334. PMC: 6233320. DOI: 10.1080/10409238.2018.1458071. View

16.

Ju H, Zhuang Z, Li H, Tian T, Lu Y, Fan X . Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Lett. 2016; 379(1):1-11. DOI: 10.1016/j.canlet.2016.05.024. View

17.

Wang J, Wu J, Wang L, Min X, Chen Z . The LINC00152/miR-138 Axis Facilitates Gastric Cancer Progression by Mediating SIRT2. J Oncol. 2021; 2021:1173869. PMC: 8541877. DOI: 10.1155/2021/1173869. View

18.

Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y . Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006; 8(9):1025-31. DOI: 10.1038/ncb1468. View

19.

Zhang L, Liu L, Qie L, Ling K, Xu L, Wang F . Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase. Eur J Pharmacol. 2011; 674(2-3):163-70. DOI: 10.1016/j.ejphar.2011.11.017. View

20.

Liu L, Li Y, Cao D, Qiu S, Li Y, Jiang C . SIRT3 inhibits gallbladder cancer by induction of AKT-dependent ferroptosis and blockade of epithelial-mesenchymal transition. Cancer Lett. 2021; 510:93-104. DOI: 10.1016/j.canlet.2021.04.007. View